Skip to content
Resolve Therapeutics, LLC.
Resolve Therapeutics, LLC.Resolve Therapeutics, LLC.
  • About Us
    • Our Company
    • Management Team
    • Clinical Advisory Board
    • Contact Us
  • Product Candidates
    • Our Pipeline
    • RSLV-132
    • Clinical Trials
  • Science
    • Nuclease Therapy Platform
    • Publications
  • Therapeutic Need
    • Lupus
    • Sjögren’s syndrome
    • Patient Resources & Advocacy
  • News
  • About Us
    • Our Company
    • Management Team
    • Clinical Advisory Board
    • Contact Us
  • Product Candidates
    • Our Pipeline
    • RSLV-132
    • Clinical Trials
  • Science
    • Nuclease Therapy Platform
    • Publications
  • Therapeutic Need
    • Lupus
    • Sjögren’s syndrome
    • Patient Resources & Advocacy
  • News

Category Archives: News

RSLV-132 Demonstrates Clinically Meaningful Improvement in Patients With Systemic Lupus Erythematosus in Phase 2a Clinical Trial

NewsBy We Are Design PoolDecember 8, 2020

RSLV-132 Demonstrates Clinically Meaningful Improvement in Patients With Systemic Lupus Erythematosus in Phase 2a Clinical Trial

Resolve Therapeutics Publishes Positive Sjögren’s Syndrome Clinical Trial Results

NewsBy We Are Design PoolDecember 8, 2020

Resolve Therapeutics Publishes Positive Sjögren’s Syndrome Clinical Trial Results

Resolve Therapeutics Announces Completion of Enrollment for Phase 2a Study of RSLV-132 for the Treatment of Lupus

NewsBy resolve-adminJuly 22, 2019

Resolve Therapeutics Announces Completion of Enrollment for Phase 2a Study of RSLV-132 for the Treatment of Lupus

Resolve Therapeutics Announces RSLV-132 Significantly Reduces Fatigue in Phase II Study of Patients with Sjögren’s Syndrome

NewsBy resolve-adminJune 13, 2019

Resolve Therapeutics Announces RSLV-132 Significantly Reduces Fatigue in Phase II Study of Patients with Sjögren’s Syndrome

Resolve Therapeutics To Present Phase II Data on Lead Product Candidate RSLV-132 at the 2019 EULAR European Congress of Rheumatology

NewsBy resolve-adminJune 10, 2019

Resolve Therapeutics To Present Phase II Data on Lead Product Candidate RSLV-132 at the 2019 EULAR European Congress of Rheumatology

Resolve Therapeutics Announces Publication of Clinical Data Demonstrating the Role of Circulating RNA in Systemic Lupus Erythematosus

NewsBy resolve-adminAugust 22, 2016

Resolve Therapeutics Announces Publication of Clinical Data Demonstrating the Role of Circulating RNA in Systemic Lupus Erythematosus

Resolve to Present Data on Lupus Studies at International Rheumatology Conference

NewsBy resolve-adminMay 26, 2016

Resolve to Present Data on Lupus Studies at International Rheumatology Conference

Resolve Announces Positive Clinical Data from RSLV-132 Lupus Study

NewsBy Resolve TherapeuticsFebruary 10, 2016

Resolve Announces Positive Clinical Data from RSLV-132 Lupus Study

Resolve Initiates RSLV-132 Clinical Studies

NewsBy Resolve TherapeuticsMarch 17, 2014

Resolve Initiates RSLV-132 Clinical Studies

Takeda and Resolve Therapeutics Enter Autoimmune Partnership

NewsBy Resolve TherapeuticsFebruary 27, 2013

Takeda and Resolve Therapeutics Enter Autoimmune Partnership

12
© 2020 Resolve Therapeutics. All rights reserved.

Sitemap   Terms of Use   Privacy Policy  

Go to Top